Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

NCT00555152 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

22

Enrollment

NIH

Sponsor class

Conditions

Ductal Breast Carcinoma In Situ
HER2/Neu Positive

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Lapatinib Ditosylate
OTHER: Placebo

Sponsor

National Cancer Institute (NCI)